文献速递母胎医学产科

胎儿血样对确定先天性巨细胞病毒感染预后的贡献:瑞士的病例-队列研究

Contribution of fetal blood sampling to determining the prognosis of congenital cytomegalovirus infections: a case-cohort study in Switzerland.
PubMed 文献 · Am J Obstet Gynecol · 2024-03-26

该病例-队列研究纳入58例先天性巨细胞病毒感染胎儿,在21-28周行胎儿血样采集,比较中重度症状性与无症状至轻度感染胎儿的血液参数。血小板、β2微球蛋白和病毒载量可预测中重度症状性感染,联合胎儿脑影像的递归算法阴性预测值为100%。

要点

  • 胎儿血样中血小板、β2微球蛋白和巨细胞病毒载量可辅助判断先天性巨细胞病毒感染预后。
  • 先做胎儿脑影像、后行胎儿血样(血小板<120,000/mL、病毒血症≥5 log10/mL、β2微球蛋白≥12 mg/L)的递归算法阴性预测值为100%。
  • 58例胎儿中25例(43%)为中重度症状性感染。

核心结论

  • 胎儿血中血小板、β2微球蛋白和巨细胞病毒载量的组合可用于预后判断,尤其适用于产前诊断时无严重脑异常的巨细胞病毒感染胎儿。
  • 未来研究应评估这些参数在胎儿血样采集前接受过伐昔洛韦治疗的感染胎儿中是否仍然有用。

研究设计与样本

  • 病例-队列研究,在瑞士开展。
  • 对孕21-28周、经羊膜腔穿刺确诊先天性巨细胞病毒感染的胎儿行胎儿血样采集,比较中重度症状性感染与无症状至轻度感染胎儿的血液参数。
  • 共纳入58例胎儿,活产儿中位随访36个月。

主要发现

  • 58例胎儿中25例(43%)为中重度症状性感染:16例严重脑异常,5例出生时有多项体征或症状,2例双侧感音神经性听力损失,2例神经发育迟缓。
  • 中重度症状性感染胎儿与无症状至轻度感染胎儿之间,血小板、天冬氨酸氨基转移酶、β2微球蛋白、免疫球蛋白M和巨细胞病毒载量值存在显著差异。

关键数值与推荐

  • 预测中重度症状性感染的最佳策略为先行胎儿脑影像,后行胎儿血样采集,切点为血小板<120,000/mL、病毒血症≥5 log10/mL、β2微球蛋白≥12 mg/L。
  • 该递归算法对中重度症状性感染的阴性预测值为100%。

临床怎么用

  • 作者认为,胎儿血中血小板、β2微球蛋白和巨细胞病毒载量的组合可用于预后判断,尤其适用于产前诊断时无严重脑异常的巨细胞病毒感染胎儿。
  • 作者建议未来研究应评估这些参数在胎儿血样采集前接受过伐昔洛韦治疗的感染胎儿中是否仍然有用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytomegalovirus is responsible for the most common congenital infection, affecting 0.5% to 1.0% of live births in Europe. Congenital cytomegalovirus infection can be diagnosed during pregnancy by viral DNA amplification in the amniotic fluid, but the prognosis of fetuses without severe brain abnormalities remains difficult to establish on the basis of prenatal imaging alone. OBJECTIVE: To identify predictors of moderate to severe symptomatic cytomegalovirus infection among fetal blood parameters and to propose an algorithm on the basis of these parameters and on prenatal imaging that would provide the best positive and negative predictive values. STUDY DESIGN: Fetal blood sampling at 21-28 weeks gestation was performed in fetuses with congenital cytomegalovirus infection confirmed by amniocentesis after maternal infection in the first-trimester or periconceptional period. We compared the levels of hemoglobin, thrombocytes, γ-glutamyl transpeptidase, aspartate aminotransferase, alanine aminotransferase, β2-microglobulin, immunoglobulins G and M, and cytomegalovirus DNA viral loads in amniotic fluid and fetal blood between those with moderate to severe symptomatic infection and those with asymptomatic to mild infection (median follow-up of 36 months for live births). RESULTS: Among 58 fetuses included, 25 (43%) had a moderate to severe symptomatic infection: 16 with severe cerebral abnormalities, 5 with multiple signs or symptoms at birth, 2 with bilateral sensorineural hearing loss, and 2 with neurodevelopmental delay. The values of thrombocytes, aspartate aminotransferase, β2 microglobulin, Immunoglobulin M, and cytomegalovirus viral loads differed significantly between fetuses with moderate to severe symptomatic infection and those with asymptomatic to mild infection. The optimal strategy to predict moderate to severe symptomatic infection was to first perform fetal brain imaging, followed by fetal blood sampling with the following cutoffs: thrombocytes <120,000/mL, viremia ≥5 log10/mL, and β2 microglobulin ≥12 mg/L). This recursive algorithm had a negative predictive value of 100% for moderately to severely symptomatic infection. CONCLUSION: The combination of thrombocytes, β2-microglobulin, and cytomegalovirus viral load in fetal blood can be used for prognosis determination, particularly in cytomegalovirus-infected fetuses without severe brain abnormalities at the time of prenatal diagnosis. Future studies should evaluate whether these parameters remain useful in infected fetuses who have been treated with valacyclovir before fetal blood sampling.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pomar L, Contier A, Stojanov M, et al. Contribution of fetal blood sampling to determining the prognosis of congenital cytomegalovirus infections: a case-cohort study in Switzerland. Am J Obstet Gynecol. 2024. PMID: 38527603. doi:10.1016/j.ajog.2024.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。